JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Etiologies of spontaneous pneumomediastinum in children of different ages.

BACKGROUND: Spontaneous pneumomediastinum (SPM), while rare, is probably underestimated in children. Treatments for SPM target the underlying disease and trigger factors. This study aimed to analyze the etiology of SPM in different age groups.

METHODS: A total of 18 children with SPM were analyzed in the Children's Medical Center at China Medical University Hospital between 1997 and 2007.

RESULTS: The incidence of SPM in children was 1:8,302 patients at the Department of Pediatric Emergency Medicine. A bimodal peak in incidence occurred in those younger than 4 years old and in those aged 15-18 years. Characteristic symptoms were dyspnea (77.8%), followed by chest pain (66.7%) and neck pain (44.4%); common specific physical signs were subcutaneous emphysema (55.6%) and Hammer's sign (11.1%). Trigger factors were infection (44.4%), with a mean age of 5.8+5.0 years, and diabetic ketoacidosis (5.6%), with a mean age of 18 years. Idiopathic SPM accounted for 50.0% of patients, with mean age 14.4 +/- 1.8 years. In terms of the age distribution, five (27.8%; males/females=4:1) preschoolers (<6 years old) developed SPM, mostly due to infectious disease. Two girls aged less than 10 years developed asthma in later years. All eight male adolescents (> or =10 years) developed SPM due to idiopathic factors. Of nine boys with idiopathic SPM, six underwent strenuous exercise before developing SPM. Mean hospitalization was 7.9 +/- 11.5 days and 11 (61.1%) patients needed intensive care. Nearly all of the patients had complete resolution on chest radiography before discharge.

CONCLUSION: Clinicians should be alert to the risk of SPM based on the presence of these symptoms. The etiology of SPM varies with age. Treatment of SPM must target the trigger factors or the underlying disease.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app